Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 132244 | Registry Identifier | JAPIC-CTI |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a study to evaluate the efficacy and safety of desloratadine (MK-4117) in Japanese participants with perennial allergic rhinitis. The primary hypothesis is that desloratadine is superior to placebo after 2 weeks of treatment with regard to change from baseline in Total Nasal Symptom Score among Japanese participants with perennial allergic rhinitis.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Desloratadine 5 mg | Experimental | Participants receive one desloratadine 5 mg tablet and one placebo tablet orally once daily for up to 2 weeks |
|
| Desloratadine 10 mg | Experimental | Participants receive two desloratadine 5 mg tablets orally once daily for up to 2 weeks |
|
| Placebo | Placebo Comparator | Participants receive two placebo tablets orally once daily for up to 2 weeks |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Desloratadine 5 mg | Drug | Desloratadine 5 mg tablets |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline in Total Nasal Symptom Score (TNSS) Assessed by the Investigator at Week 2 | The investigator interviewed and examined participants to evaluate for nasal symptoms of: sneezing (daily frequency of attacks; score of 0=less than 1 time to 3=11+ times), rhinorrhea (daily frequency of blowing nose; score of 0=less than 1 time to 3=11+ times), nasal congestion (score of 0=less than nasal blockage without oral breathing to 3=severe nasal blockage causing prolonged oral breathing in a day), and nasal itching (score of 0=none to 3=nose is itchy, requiring frequent rubbing or blowing nose). The TNSS is the sum of the 4 nasal symptom sub-scores. TNSS scores could range from 0 to 12, with a higher score indicating more frequent/severe nasal symptoms. | Baseline and Week 2 |
| Number of Participants Experiencing an Adverse Event (AE) | An AE is defined as any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of the study drug or protocol-specified procedure, whether or not considered related to the study drug or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that is temporally associated with the use of the study drug, is also an AE. The number of participants who experienced an AE, regardless of causality or severity, was summarized. | Up to Week 4 |
| Number of Participants Discontinuing Study Drug Due to an AE | An AE is defined as any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of the study drug or protocol-specified procedure, whether or not considered related to the study drug or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that is temporally associated with the use of the study drug, is also an AE. The number of participants who discontinued study drug, whether permanently or temporarily, due to an AE was summarized. | Up to Week 2 |
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline in Total Nasal Symptom Score (TNSS) Assessed by the Investigator at Day 3 and Week 1 | The investigator interviewed and examined participants to evaluate for nasal symptoms of: sneezing (daily frequency of attacks; score of 0=less than 1 time to 3=11+ times), rhinorrhea (daily frequency of blowing nose; score of 0=less than 1 time to 3=11+ times), nasal congestion (score of 0=less than nasal blockage without oral breathing to 3=severe nasal blockage causing prolonged oral breathing in a day), and nasal itching (score of 0=none to 3=nose is itchy, requiring frequent rubbing or blowing nose). The TNSS is the sum of the 4 nasal symptom sub-scores. TNSS scores could range from 0 to 12, with a higher score indicating more frequent/severe nasal symptoms. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| Result | Okamoto Y, Maeda Y, Oshima N, Hisada S. A Phase III clinical trial of desloratadine in Japanese subjects with perennial allergic rhinitis: A randomized controlled trial. J Clin Therapeut Med. 2016;32(12):967-978 [in Japanese] https://mol.medicalonline.jp/archive/search?jo=an9cltmd&ye=2016&vo=32&issue=12 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Desloratadine 5 mg | Participants receive one desloratadine 5 mg tablet and one placebo tablet orally once daily for up to 2 weeks |
| FG001 | Desloratadine 10 mg | Participants receive two desloratadine 5 mg tablets orally once daily for up to 2 weeks |
| FG002 | Placebo | Participants receive two placebo tablets orally once daily for up to 2 weeks |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Desloratadine 5 mg | Participants receive one desloratadine 5 mg tablet and one placebo tablet orally once daily for up to 2 weeks |
| BG001 | Desloratadine 10 mg | Participants receive two desloratadine 5 mg tablets orally once daily for up to 2 weeks |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Change From Baseline in Total Nasal Symptom Score (TNSS) Assessed by the Investigator at Week 2 | The investigator interviewed and examined participants to evaluate for nasal symptoms of: sneezing (daily frequency of attacks; score of 0=less than 1 time to 3=11+ times), rhinorrhea (daily frequency of blowing nose; score of 0=less than 1 time to 3=11+ times), nasal congestion (score of 0=less than nasal blockage without oral breathing to 3=severe nasal blockage causing prolonged oral breathing in a day), and nasal itching (score of 0=none to 3=nose is itchy, requiring frequent rubbing or blowing nose). The TNSS is the sum of the 4 nasal symptom sub-scores. TNSS scores could range from 0 to 12, with a higher score indicating more frequent/severe nasal symptoms. | The Full Analysis Set (FAS) population consisted of all participants who took at least one dose of study drug and had a baseline or at least one post-baseline assessment for TNSS. | Posted | Least Squares Mean | 95% Confidence Interval | Score on a Scale | Baseline and Week 2 |
|
Up to 2 weeks after last dose of study drug (up to 4 weeks)
The population consisted of all participants who received at least one dose of study drug.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Desloratadine 5 mg | Participants receive one desloratadine 5 mg tablet and one placebo tablet orally once daily for up to 2 weeks |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Epilepsy | Nervous system disorders | MedDRA 16.1 | Systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Nasphopharyngitis | Infections and infestations | MedDRA 16.1 | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Senior Vice President, Global Clinical Development | Merck Sharp & Dohme Corp. | 1-800-672-6372 | ClinicalTrialsDisclosure@merck.com |
| ID | Term |
|---|---|
| D012221 | Rhinitis, Allergic, Perennial |
| D012220 | Rhinitis |
| D065631 | Rhinitis, Allergic |
| D009668 | Nose Diseases |
| D012140 | Respiratory Tract Diseases |
| D007154 | Immune System Diseases |
| ID | Term |
|---|---|
| D012130 | Respiratory Hypersensitivity |
| D010038 | Otorhinolaryngologic Diseases |
| D006969 | Hypersensitivity, Immediate |
| D006967 | Hypersensitivity |
Not provided
Not provided
| ID | Term |
|---|---|
| C121345 | desloratadine |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Drug | Matching placebo to desloratadine 5 mg tablets |
|
| Baseline and Day 3, Week 1 |
| Change From Baseline in Nasal Symptom Sub-Scores Assessed by the Investigator | The investigator interviewed and examined participants to evaluate for nasal symptoms of: sneezing (daily frequency of attackes; score of 0=less than 1 time to 3=11+ times), rhinorrhea (daily frequency of blowing nose; score of 0=less than 1 time to 3=11+ times), nasal congestion (score of 0=less than nasal blockage without oral breathing to 3=severe nasal blockage causing prolonged oral breathing in a day), and nasal itching (score of 0=none to 3=nose is itchy, requiring frequent rubbing or blowing nose). Nasal symptom sub-scores could range from 0 to 3, with a higher nasal symptom sub-score indicating more frequent/severe nasal symptoms. | Baseline and Day 3, Week 1, Week 2 |
| Change From Baseline in Nasal Finding Score Assessed by the Investigator | The investigator conducted rhinoscopic examinations on participants to evaluate: swelling of inferior nasal concha mucosa (INCM) (score of 0=none to 3=middle nasal concha is not visible), coloring of inferior nasal concha mucosa (INCM) (score of 0=normal to 3=pale), and nasal discharge production (NDP) (score of 0=none to 3=congesting). The score for each nasal finding component could range from 0 to 3, with a higher score indicating more severe symptoms. | Baseline and Day 3, Week 1, Week 2 |
| Change From Baseline in Eye Symptom Score Assessed by the Investigator | The investigator interviewed and examined participants for eye (itching) symptoms (score of 0=none to 3=eye is itchy, requiring frequent rubbing of eye). Eye symptom scores could range from 0 to 3, with a higher score indicating greater eye itchiness. | Baseline and Day 3, Week 1, Week 2 |
| Number of Participants With Moderate-to-Remarkable Improvement in Global Improvement Assessed by the Investigator | The investigator comprehensively evaluated participants on global improvement according to 5 grades: 1=remarkably improved, 2= moderately improved, 3=slightly improved, 4=unchanged, and 5=aggravated. The number of participants who were evaluated as remarkably improved and moderately improved was calculated. | Day 3, Week 1, Week 2 |
| Change From Baseline in Score on Interference With Daily Activities Assessed by the Investigator | The investigator interviewed participants at Baseline, Day 3, Week 1 and Week 2 to evaluate interference with daily activities according to the following scale: 0=none, 1=nasal symptom interferes with daily activities from time to time (+), 2=between 1 and 3 (++), and 3=nasal symtom interferes with daily activity often (+++). Interference with daily activities scores could range from 0 to 3, with a higher score indicating greater interference with daily activities. | Baseline and Day 3, Week 1, Week 2 |
| Change From Baseline in Nasal Symptom Sub-Scores Reported in Participant Diaries | Participants evaluated themselves in their daily allergy diaries for nasal symptoms of: sneezing (daily frequency of attacks; score of 0=less than 1 time to 3=11+ times), rhinorrhea (daily frequency of blowing nose; score of 0=less than 1 time to 3=11+ times), nasal congestion (score of 0=less than nasal blockage without oral breathing to 3=severe nasal blockage causing prolonged oral breathing in a day), and nasal itching (score of 0=none to 3=nose is itchy, requiring frequent rubbing or blowing nose). Each nasal symptom sub-score could range from 0 to 3, with a higher sub-score indicating more frequent/severe nasal symptoms. | Baseline and Day 3, Week 1, Week 2 |
| Change From Baseline in Eye Symptom Score Reported in Participant Diaries | Participants evaluated themselves in their daily allergy diaries for eye (itching) symptoms (score of 0=none to 3=eye is itchy, requiring frequent rubbing of eye). Eye symptom scores could range from 0 to 3, with a higher score indicating greater eye itchiness. | Baseline and Day 3, Week 1, Week 2 |
| Protocol Violation |
|
| Withdrawal by Subject |
|
| BG002 | Placebo | Participants receive two placebo tablets orally once daily for up to 2 weeks |
| BG003 | Total | Total of all reporting groups |
| Years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| OG000 |
| Desloratadine 5 mg |
Participants receive one desloratadine 5 mg tablet and one placebo tablet orally once daily for up to 2 weeks |
| OG001 | Desloratadine 10 mg | Participants receive two desloratadine 5 mg tablets orally once daily for up to 2 weeks |
| OG002 | Placebo | Participants receive two placebo tablets orally once daily for up to 2 weeks |
|
|
|
| Primary | Number of Participants Experiencing an Adverse Event (AE) | An AE is defined as any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of the study drug or protocol-specified procedure, whether or not considered related to the study drug or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that is temporally associated with the use of the study drug, is also an AE. The number of participants who experienced an AE, regardless of causality or severity, was summarized. | The All-Subjects-as-Treated (ASaT) population consisted of all participants who received at least one dose of study drug. | Posted | Number | Participants | Up to Week 4 |
|
|
|
| Primary | Number of Participants Discontinuing Study Drug Due to an AE | An AE is defined as any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of the study drug or protocol-specified procedure, whether or not considered related to the study drug or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that is temporally associated with the use of the study drug, is also an AE. The number of participants who discontinued study drug, whether permanently or temporarily, due to an AE was summarized. | The ASaT population consisted of all participants who received at least one dose of study drug. | Posted | Number | Participants | Up to Week 2 |
|
|
|
| Secondary | Change From Baseline in Total Nasal Symptom Score (TNSS) Assessed by the Investigator at Day 3 and Week 1 | The investigator interviewed and examined participants to evaluate for nasal symptoms of: sneezing (daily frequency of attacks; score of 0=less than 1 time to 3=11+ times), rhinorrhea (daily frequency of blowing nose; score of 0=less than 1 time to 3=11+ times), nasal congestion (score of 0=less than nasal blockage without oral breathing to 3=severe nasal blockage causing prolonged oral breathing in a day), and nasal itching (score of 0=none to 3=nose is itchy, requiring frequent rubbing or blowing nose). The TNSS is the sum of the 4 nasal symptom sub-scores. TNSS scores could range from 0 to 12, with a higher score indicating more frequent/severe nasal symptoms. | The FAS population consisted of all participants who took at least one dose of study drug and had a baseline or at least one post-baseline assessment for TNSS. | Posted | Least Squares Mean | 95% Confidence Interval | Score on a Scale | Baseline and Day 3, Week 1 |
|
|
|
|
| Secondary | Change From Baseline in Nasal Symptom Sub-Scores Assessed by the Investigator | The investigator interviewed and examined participants to evaluate for nasal symptoms of: sneezing (daily frequency of attackes; score of 0=less than 1 time to 3=11+ times), rhinorrhea (daily frequency of blowing nose; score of 0=less than 1 time to 3=11+ times), nasal congestion (score of 0=less than nasal blockage without oral breathing to 3=severe nasal blockage causing prolonged oral breathing in a day), and nasal itching (score of 0=none to 3=nose is itchy, requiring frequent rubbing or blowing nose). Nasal symptom sub-scores could range from 0 to 3, with a higher nasal symptom sub-score indicating more frequent/severe nasal symptoms. | The FAS population consisted of all participants who took at least one dose of study drug and had a baseline or at least one post-baseline assessment for nasal symptom sub-scores as assessed by the investigator. | Posted | Least Squares Mean | 95% Confidence Interval | Score on a Scale | Baseline and Day 3, Week 1, Week 2 |
|
|
|
|
| Secondary | Change From Baseline in Nasal Finding Score Assessed by the Investigator | The investigator conducted rhinoscopic examinations on participants to evaluate: swelling of inferior nasal concha mucosa (INCM) (score of 0=none to 3=middle nasal concha is not visible), coloring of inferior nasal concha mucosa (INCM) (score of 0=normal to 3=pale), and nasal discharge production (NDP) (score of 0=none to 3=congesting). The score for each nasal finding component could range from 0 to 3, with a higher score indicating more severe symptoms. | The FAS population consisted of all participants who took at least one dose of study drug and had a baseline or at least one post-baseline assessment for nasal finding score. | Posted | Least Squares Mean | 95% Confidence Interval | Score on a Scale | Baseline and Day 3, Week 1, Week 2 |
|
|
|
|
| Secondary | Change From Baseline in Eye Symptom Score Assessed by the Investigator | The investigator interviewed and examined participants for eye (itching) symptoms (score of 0=none to 3=eye is itchy, requiring frequent rubbing of eye). Eye symptom scores could range from 0 to 3, with a higher score indicating greater eye itchiness. | The FAS population consisted of all participants who took at least one dose of study drug and had a baseline or at least one post-baseline assessment for eye symptom score as assessed by the investigator. | Posted | Least Squares Mean | 95% Confidence Interval | Score on a Scale | Baseline and Day 3, Week 1, Week 2 |
|
|
|
|
| Secondary | Number of Participants With Moderate-to-Remarkable Improvement in Global Improvement Assessed by the Investigator | The investigator comprehensively evaluated participants on global improvement according to 5 grades: 1=remarkably improved, 2= moderately improved, 3=slightly improved, 4=unchanged, and 5=aggravated. The number of participants who were evaluated as remarkably improved and moderately improved was calculated. | The FAS population consisted of all participants who took at least one dose of study drug and had a baseline or at least one post-baseline assessment for global improvement. | Posted | Number | Participants | Day 3, Week 1, Week 2 |
|
|
|
|
| Secondary | Change From Baseline in Score on Interference With Daily Activities Assessed by the Investigator | The investigator interviewed participants at Baseline, Day 3, Week 1 and Week 2 to evaluate interference with daily activities according to the following scale: 0=none, 1=nasal symptom interferes with daily activities from time to time (+), 2=between 1 and 3 (++), and 3=nasal symtom interferes with daily activity often (+++). Interference with daily activities scores could range from 0 to 3, with a higher score indicating greater interference with daily activities. | The FAS population consisted of all participants who took at least one dose of study drug and had a baseline or at least one post-baseline assessment for interference with daily activities. | Posted | Least Squares Mean | 95% Confidence Interval | Score on a Scale | Baseline and Day 3, Week 1, Week 2 |
|
|
|
|
| Secondary | Change From Baseline in Nasal Symptom Sub-Scores Reported in Participant Diaries | Participants evaluated themselves in their daily allergy diaries for nasal symptoms of: sneezing (daily frequency of attacks; score of 0=less than 1 time to 3=11+ times), rhinorrhea (daily frequency of blowing nose; score of 0=less than 1 time to 3=11+ times), nasal congestion (score of 0=less than nasal blockage without oral breathing to 3=severe nasal blockage causing prolonged oral breathing in a day), and nasal itching (score of 0=none to 3=nose is itchy, requiring frequent rubbing or blowing nose). Each nasal symptom sub-score could range from 0 to 3, with a higher sub-score indicating more frequent/severe nasal symptoms. | The FAS population consisted of all participants who took at least one dose of study drug and had a baseline or at least one post-baseline assessment for participant-rated nasal symptom score. | Posted | Least Squares Mean | 95% Confidence Interval | Score on a Scale | Baseline and Day 3, Week 1, Week 2 |
|
|
|
|
| Secondary | Change From Baseline in Eye Symptom Score Reported in Participant Diaries | Participants evaluated themselves in their daily allergy diaries for eye (itching) symptoms (score of 0=none to 3=eye is itchy, requiring frequent rubbing of eye). Eye symptom scores could range from 0 to 3, with a higher score indicating greater eye itchiness. | The FAS population consisted of all participants who took at least one dose of study drug and had a baseline or at least one post-baseline assessment for participant-rated eye symptom score. | Posted | Least Squares Mean | 95% Confidence Interval | Score on a Scale | Baseline and Day 3, Week 1, Week 2 |
|
|
|
|
| 1 |
| 202 |
| 11 |
| 202 |
| EG001 | Desloratadine 10 mg | Participants receive two desloratadine 5 mg tablets orally once daily for up to 2 weeks | 0 | 203 | 17 | 203 |
| EG002 | Placebo | Participants receive two placebo tablets orally once daily for up to 2 weeks | 0 | 201 | 9 | 201 |
The sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation.
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
| Change from BL at Week 1 |
|
| Constrained Longitudinal Data Analysis |
Model with terms for visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable |
| 0.013 |
| Difference in LS Means |
| -0.46 |
| 2-Sided |
| 95 |
| -0.82 |
| -0.10 |
Difference in LS Means for Change from Baseline in TNSS at Day 3 |
| Superiority or Other (legacy) |
| Constrained Longitudinal Data Analysis | Model with terms for visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable | 0.569 | Difference in LS Means | 0.12 | 2-Sided | 95 | -0.29 | 0.53 | Difference in LS Means for Change from Baseline in TNSS at Week 1 | Superiority or Other (legacy) |
| Constrained Longitudinal Data Analysis | Model with terms for visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable | 0.685 | Difference in LS Means | 0.09 | 2-Sided | 95 | -0.33 | 0.50 | Difference in LS Means for Change from Baseline in TNSS at Week 1 | Superiority or Other (legacy) |
| Sneezing: Change from BL at Week 1 |
|
| Sneezing: Change from BL at Week 2 |
|
| Rhinorrhea: Change from BL at Day 3 |
|
| Rhinorrhea: Change from BL at Week 1 |
|
| Rhinorrhea: Change from BL at Week 2 |
|
| Nasal Congestion: Change from BL at Day 3 |
|
| Nasal Congestion: Change from BL at Week 1 |
|
| Nasal Congestion: Change from BL at Week 2 |
|
| Nasal Itching: Change from BL at Day 3 |
|
| Nasal Itching: Change from BL at Week 1 |
|
| Nasal Itching: Change from BL at Week 2 |
|
| Constrained Longitudinal Data Analysis |
Model with terms for visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable |
| 0.067 |
| Difference in LS Means |
| -0.10 |
| 2-Sided |
| 95 |
| -0.22 |
| 0.01 |
Difference in LS Means for Change From Baseline in Sneezing Nasal Symptom Sub-Score at Week 2 |
| Superiority or Other (legacy) |
| Constrained Longitudinal Data Analysis | Model with terms for visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable | 0.895 | Difference in LS Means | -0.01 | 2-Sided | 95 | -0.15 | 0.13 | Difference in LS Means for Change From Baseline in Rhinorrhea Nasal Symptom Sub-Score at Week 2 | Superiority or Other (legacy) |
| Constrained Longitudinal Data Analysis | Model with terms for visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable | 0.627 | Difference in LS Means | 0.03 | 2-Sided | 95 | -0.10 | 0.17 | Difference in LS Means for Change From Baseline in Rhinorrhea Nasal Symptom Sub-Score at Week 2 | Superiority or Other (legacy) |
| Constrained Longitudinal Data Analysis | Model with terms for visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable | 0.535 | Difference in LS Means | 0.04 | 2-Sided | 95 | -0.09 | 0.18 | Difference in LS Means for Change From Baseline in Nasal Congestion Nasal Symptom Sub-Score at Week 2 | Superiority or Other (legacy) |
| Constrained Longitudinal Data Analysis | Model with terms for visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable | 0.557 | Difference in LS Means | 0.04 | 2-Sided | 95 | -0.10 | 0.18 | Difference in LS Means for Change From Baseline in Nasal Congestion Nasal Symptom Sub-Score at Week 2 | Superiority or Other (legacy) |
| Constrained Longitudinal Data Analysis | Model with terms for visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable | 0.119 | Difference in LS Means | -0.11 | 2-Sided | 95 | -0.25 | 0.03 | Difference in LS Means for Change From Baseline in Nasal Itching Nasal Symptom Sub-Score at Week 2 | Superiority or Other (legacy) |
| Constrained Longitudinal Data Analysis | Model with terms for visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable | 0.403 | Difference in LS Means | -0.06 | 2-Sided | 95 | -0.20 | 0.08 | Difference in LS Means for Change From Baseline in Nasal Itching Nasal Symptom Sub-Score at Week 2 | Superiority or Other (legacy) |
| Swelling of INCM: Change from BL at Week 1 |
|
| Swelling of INCM: Change from BL at Week 2 |
|
| Coloring of INCM: Change from BL at Day 3 |
|
| Coloring of INCM: Change from BL at Week 1 |
|
| Coloring of INCM: Change from BL at Week 2 |
|
| NDP: Change from BL at Day 3 |
|
| NDP: Change from BL at Week 1 |
|
| NDP: Change from BL at Week 2 |
|
| Constrained Longitudinal Data Analysis |
Model with terms for visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable |
| 0.714 |
| Difference in LS Means |
| -0.03 |
| 2-Sided |
| 95 |
| -0.16 |
| 0.11 |
Difference in LS Means for Change From Baseline in Swelling of INCM at Week 2 |
| Superiority or Other (legacy) |
| Constrained Longitudinal Data Analysis | Model with terms for visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable | 0.725 | Difference in LS Means | -0.03 | 2-Sided | 95 | -0.19 | 0.13 | Difference in LS Means for Change From Baseline in Coloring of INCM at Week 2 | Superiority or Other (legacy) |
| Constrained Longitudinal Data Analysis | Model with terms for visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable | 0.708 | Difference in LS Means | -0.03 | 2-Sided | 95 | -0.19 | 0.13 | Difference in LS Means for Change From Baseline in Coloring of INCM at Week 2 | Superiority or Other (legacy) |
| Constrained Longitudinal Data Analysis | Model with terms for visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable | 0.680 | Difference in LS Means | 0.03 | 2-Sided | 95 | -0.10 | 0.16 | Difference in LS Means for Change From Baseline in NDP at Week 2 | Superiority or Other (legacy) |
| Constrained Longitudinal Data Analysis | Model with terms for visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable | 0.373 | Difference in LS Means | 0.06 | 2-Sided | 95 | -0.07 | 0.19 | Difference in LS Means for Change From Baseline in NDP at Week 2 | Superiority or Other (legacy) |
| Change from BL at Week 1 |
|
| Change from BL at Week 2 |
|
| Constrained Longitudinal Data Analysis |
Model with terms for visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable |
| 0.260 |
| Difference in LS Means |
| -0.07 |
| 2-Sided |
| 95 |
| -0.20 |
| 0.06 |
Difference in LS Means for Change From Baseline in Eye Symptom Score at Week 2 |
| Superiority or Other (legacy) |
|
| Week 2 (n=200, 203, 201) |
|
|
| Regression, Logistic |
Logistic model with global improvement rate as response variable and treatment, age strata, and severity as factors |
| 0.159 |
| Odds Ratio (OR) |
| 0.755 |
| 2-Sided |
| 95 |
| 0.510 |
| 1.116 |
Difference in the number of participants with moderate or remarkable improvement at Week 2. An odds ratio >1 is in favor of the first group of the pairwise comparison. |
| Superiority or Other (legacy) |
| Change from BL at Week 1 |
|
| Change from BL at Week 2 |
|
| Constrained Longitudinal Data Analysis |
Model with terms for visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable |
| 0.782 |
| Difference in LS Means |
| -0.02 |
| 2-Sided |
| 95 |
| -0.13 |
| 0.10 |
Difference in LS Means for Change from Baseline in Interference with Daily Activities at Week 2 |
| Superiority or Other (legacy) |
| Sneezing: Change from BL at Week 1 |
|
| Sneezing: Change from BL at Week 2 |
|
| Rhinorrhea: Change from BL at Day 3 |
|
| Rhinorrhea: Change from BL at Week 1 |
|
| Rhinorrhea: Change from BL at Week 2 |
|
| Nasal Congestion: Change from BL at Day 3 |
|
| Nasal Congestion: Change from BL at Week 1 |
|
| Nasal Congestion: Change from BL at Week 2 |
|
| Nasal Itching: Change from BL at Day 3 |
|
| Nasal Itching: Change from BL at Week 1 |
|
| Nasal Itching: Change from BL at Week 2 |
|
| Constrained Longitudinal Data Analysis |
Model with terms for visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable |
| 0.098 |
| Difference in LS Means |
| -0.12 |
| 2-Sided |
| 95 |
| -0.26 |
| 0.02 |
Difference in LS Means for Change from Baseline in Sneezing at Week 2 |
| Superiority or Other (legacy) |
| Constrained Longitudinal Data Analysis | Model with terms for visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable | 0.130 | Difference in LS Means | 0.12 | 2-Sided | 95 | -0.04 | 0.27 | Difference in LS Means for Change from Baseline in Rhinorrhea at Week 2 | Superiority or Other (legacy) |
| Constrained Longitudinal Data Analysis | Model with terms for visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable | 0.375 | Difference in LS Means | 0.07 | 2-Sided | 95 | -0.08 | 0.22 | Difference in LS Means for Change from Baseline in Rhinorrhea at Week 2 | Superiority or Other (legacy) |
| Constrained Longitudinal Data Analysis | Model with terms for visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable | 0.285 | Difference in LS Means | 0.08 | 2-Sided | 95 | -0.07 | 0.24 | Difference in LS Means for Change from Baseline in Nasal Congestion at Week 2 | Superiority or Other (legacy) |
| Constrained Longitudinal Data Analysis | Model with terms for visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable | 0.490 | Difference in LS Means | 0.05 | 2-Sided | 95 | -0.10 | 0.21 | Difference in LS Means for Change from Baseline in Nasal Congestion at Week 2 | Superiority or Other (legacy) |
| Constrained Longitudinal Data Analysis | Model with terms for visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable | 0.345 | Difference in LS Means | -0.08 | 2-Sided | 95 | -0.23 | 0.08 | Difference in LS Means for Change from Baseline in Nasal Itching at Week 2 | Superiority or Other (legacy) |
| Constrained Longitudinal Data Analysis | Model with terms for visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable | 0.699 | Difference in LS Means | -0.03 | 2-Sided | 95 | -0.19 | 0.13 | Difference in LS Means for Change from Baseline in Nasal Itching at Week 2 | Superiority or Other (legacy) |
| Change from BL at Week 1 |
|
| Change from BL at Week 2 |
|
| Constrained Longitudinal Data Analysis |
Model with terms for visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable |
| 0.281 |
| Difference in LS Means |
| -0.08 |
| 2-Sided |
| 95 |
| -0.22 |
| 0.06 |
Difference in LS Means for Change from Baseline in Eye Symptom Score at Week 2 |
| Superiority or Other (legacy) |